A new study found that GPNMB, released by the brain’s immune cells, accelerates the spread of toxic alpha-synuclein. By using monoclonal antibodies to block GPNMB, the team successfully interrupted the cycle of neurodegeneration in preclinical models. This discovery provides a new therapeutic target that could finally slow the progression of Parkinson’s at its earliest stages.
